MedTrace Logo

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

NCT05688852 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2025-07-03

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.

Conditions

  • Crohn Disease

Interventions

DRUG

VTX958

Dose A VTX958

DRUG

VTX958

Dose B VTX958

DRUG

VTX958 Placebo

Placebo

Sponsors & Collaborators

  • Ventyx Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Snehal Naik, PhD · Ventyx Biosciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2024-06-27
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Bulgaria
  • Canada
  • Czechia
  • Georgia
  • Germany
  • Hungary
  • Israel
  • Italy
  • Lithuania
  • Moldova
  • Poland
  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05688852 on ClinicalTrials.gov